The document addresses
Developed in collaboration with Melanoma UK.
In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses current and emerging perspectives on the use of combination immunotherapy in oncology. These videos, developed for the UK audience, discuss the rationale for combination therapy, the data supporting the combination approaches, patient selection for combination immunotherapy versus other options, managing the more complex side effects associated with this approach, as well as new strategies of combined immunotherapy. We hope that this content will be useful for you to select and manage the best immunotherapy regimens for your cancer patients.
Rationale for Combined Immunotherapy
What are the data to support the use of combination immunotherapy?
Patient Selection for Combination Immunotherapy
Managing the Complex Adverse Effect Profile of Combination Immunotherapy
Emerging Strategies for Combination Immunotherapy
The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.
Developed in collaboration with the Melanoma UK.
Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.
Developed in collaboration with the Melanoma UK.
In the resources provided below, the AIM at Melanoma Foundation provides answers to questions and addresses misconceptions raised by patients regarding BRAF in melanoma. The patient-directed resources address what BRAF is, the role of BRAF in melanoma, what BRAF mutational status means, testing for BRAF, and the implications of the test results for treatment planning. The answers are provided by Lisa Kottschade, APRN, MSN, CNP, Associate Professor of Oncology at the Mayo Clinic in Rochester, Minnesota, and an expert faculty member of the Melanoma Nursing Initiative.
We thank Novartis Pharmaceuticals for an unrestricted educational grant in support of this important educational initiative. We also thank Gillian Nuttall of Melanoma UK for review and customization of this content for the UK audience.
Print out this pamphlet, which provides Ms. Kottschade’s commentary for specific questions/statements about BRAF.
Click on the videos below to watch Ms. Kottschade’s commentary about BRAF. Below the videos, we have also listed some resources patients might find helpful as they navigate BRAF testing and management of their melanoma.